By Stanley White
TOKYO, Nov 24 (Reuters) - Japanese shares hit multi-year
highs on Tuesday as progress in developing an inexpensive
coronavirus vaccine boosted hopes of a swift economic recovery,
with sentiment aided by a formal transition approval for U.S.
President-elect Joe Biden.
The Nikkei 225 Index .N225 ended up 2.50% at 26,165.59,
the highest close since May 1991. The broader Topix .TOPX rose
2.23% to 1,765.91, the highest in more than two years. Energy,
real estate, and financial shares led the advance.
AstraZeneca AZN.L said on Monday its COVID-19 vaccine
could be up to 90% effective, cheaper to make and easier to ship
than rival vaccines, lifting global equities. Stocks also got a boost after Biden received an approval to
begin the transition to the White House and after a report that
he would pick former Federal Reserve Chair Janet Yellen to be
the next Treasury secretary. "We're getting closer to a vaccine, and we will also get
more policy support from the incoming U.S. administration, which
are both positive for stocks," said Kiyoshi Ishigane, chief fund
manager at Mitsubishi UFJ Kokusai Asset Management Co.
Japan and many other countries are in the midst of a third
pandemic wave, and an affordable vaccine is considered essential
to end the coronavirus restrictions.
The stocks that gained the most among the top 30 core Topix
names were Shin-Etsu Chemical Co Ltd 4063.T , up 4.98%,
followed by Hoya Corp 7741.T that gained 4.54%.
The underperformers among the Topix 30 were KDDI Corp
9433.T , down 1.25%, followed by Nippon Telegraph and Telephone
Corp 9432.T that lost 1.20%.
There were 205 advancers on the Nikkei index against 19
decliners.
The volume of shares traded on the Tokyo Stock Exchange's
main board .TOPX was 1.2 billion, compared to the average of
1.15 billion in the past 30 days.